U.S. market Closed. Opens in 6 hours 8 minutes

SHLT | SHL Telemedicine Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.6500 - 2.7150
52 Week Range 2.5400 - 10.44
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 1,241
Average Volume 3,048
Shares Outstanding 16,391,428
Market Cap 44,502,727
Sector Healthcare
Industry Medical - Healthcare Information Services
IPO Date 2023-04-03
Valuation
Profitability
Growth
Health
P/E Ratio -5.12
Forward P/E Ratio N/A
EPS -0.53
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 583
Country Israel
Website SHLT
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
SHLT's peers: NRC, CPSI, HQY, NXGN, PRVA, TALK, RCM, SNCE, NH, SDGR, TDOC, VEEV, DOCS, TXG
*Chart delayed
Analyzing fundamentals for SHLT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see SHLT Fundamentals page.

Watching at SHLT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SHLT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙